Deadline: 1 February 2019
The Coalition for Epidemic Preparedness Innovations (CEPI) has launched a call for proposals (CfP3i) to develop human vaccines against Rift Valley fever and Chikungunya viruses.
The decision to fund the development of vaccines against RVF and CHIK is based on the feasibility of vaccine development and the potential public health impact of vaccines against these diseases. While vaccines against both viruses appear to be technically feasible, the commercial prospects for vaccines against RVF are non-existent and for CHIK, uncertain at best.
Funding will be provided by CEPI with anticipated support from the European Commission’s Horizon 2020 programme.
Objectives
This call for proposals invites vaccine developers to achieve the following objectives:
- For RVF vaccines: support accelerated clinical testing or activities enabling clinical testing of the most advanced RVF vaccine candidates, including identification of correlates of protection and their validation.
- For CHIK vaccines: support the rapid progression of the most advanced CHIK vaccine candidates through mid-stage and late-stage clinical development, and support activities enabling future phase III testing, including identification of correlates of protection and their validation.
Funding Information
- CfP3i presents a unique opportunity for CEPI and the European Commission to work in partnership to support the advancement and diversification of the current vaccine development pipeline against the RVF and CHIK.
- The budget of CfP3i is USD 48 million and it is expected to fund 1 to 8 projects. Funding for pre-award costs might be provided (conditions apply; see application documents). The budget for the second open call (CfP3ii) to open in 2020 is USD 100 million.
Timelines
- During the proposed project period, CEPI encourages vaccine developers to work towards the following timelines:
- Significant progress of the project should be made in the 12 to 15 months after the signing of a CEPI funding agreement
- Projects must be completed within 3 years from January 2019
- A second open call (CfP3ii) is anticipated to open in 2020, which may advance work undertaken in CfP3i.
Eligibility Criteria
- The funding opportunity through this CfP3i is open worldwide to all types of non-profit research organisations, for-profit companies, international organisations and foundations, joint R&D ventures, government research organisations, and academic institutions.
- Applicants must be legal entities, or consortia comprised of legal entities.
- At least one of the partners in the applicant organisations or consortia of partnering organisations should have experience in human vaccine development and have a track record of bringing vaccine candidates through to human clinical trials in the past 10 years.
- Applicants unable to demonstrate this experience will not be eligible for funding.
How to Apply
If applicants are planning on submitting, please inform CEPI via the given website.
For more information, please visit http://cepi.net/cfp3